Jak2 is a candidate target of genomic amplification in hematological malignancies
Iwona Włodarska(KU Leuven), Peter Marynen(Vlaams Instituut voor Biotechnologie), Jan Cools(KU Leuven), Anne Hagemeijer‐Hausman, Ruth Achten(Jessa Hospital), Sabine Franke(KU Leuven), Chris Peeters, Gregor Verhoef(Universitair Ziekenhuis Leuven), Ivan Théate, P. H. Peeters(Edith Cowan University), Lucienne Lichaux
Unknown
January 1, 2003
Cited by 0
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
|New England Journal of Medicine|2009|821
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569